Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

NCT05312411 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT05312411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05312411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-Ew) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 20, 2022
Completion date
May 31, 2040
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma